In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Metagenomi Inc (NASDAQ: MGX) closed at $1.49 down -13.87% from its previous closing price of $1.73. In other words, the price has decreased by -$13.87 from its previous closing price. On the day, 1.2 million shares were traded. MGX stock price reached its highest trading level at $1.75 during the session, while it also had its lowest trading level at $1.46.
Ratios:
For a deeper understanding of Metagenomi Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.91 and its Current Ratio is at 6.91. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on May 07, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On May 02, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $16 to $6.
On March 05, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $25.Wells Fargo initiated its Overweight rating on March 05, 2024, with a $25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 05 ’25 when Wein Matthew sold 930 shares for $1.87 per share. The transaction valued at 1,744 led to the insider holds 9,467 shares of the business.
Wapnick Pamela sold 1,808 shares of MGX for $3,390 on Mar 05 ’25. The Chief Financial Officer now owns 59,684 shares after completing the transaction at $1.87 per share. On Dec 05 ’24, another insider, Wapnick Pamela, who serves as the Chief Financial Officer of the company, sold 1,559 shares for $1.86 each. As a result, the insider received 2,900 and left with 61,492 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGX now has a Market Capitalization of 55701416 and an Enterprise Value of -146827632. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.06 while its Price-to-Book (P/B) ratio in mrq is 0.24. Its current Enterprise Value per Revenue stands at -2.808 whereas that against EBITDA is 1.759.
Stock Price History:
The Beta on a monthly basis for MGX is -0.65, which has changed by -0.7642405 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, MGX has reached a high of $8.17, while it has fallen to a 52-week low of $1.23. The 50-Day Moving Average of the stock is -14.32%, while the 200-Day Moving Average is calculated to be -41.39%.
Shares Statistics:
For the past three months, MGX has traded an average of 429.30K shares per day and 366890 over the past ten days. A total of 37.42M shares are outstanding, with a floating share count of 21.78M. Insiders hold about 41.73% of the company’s shares, while institutions hold 26.79% stake in the company. Shares short for MGX as of 1744675200 were 2761993 with a Short Ratio of 6.43, compared to 1741910400 on 2635113. Therefore, it implies a Short% of Shares Outstanding of 2761993 and a Short% of Float of 10.16.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
As of right now, 2.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.56 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$2.28 and -$2.43 for the fiscal current year, implying an average EPS of -$2.33. EPS for the following year is -$2.23, with 4.0 analysts recommending between -$0.54 and -$3.34.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $7.96M this quarter.It ranges from a high estimate of $10M to a low estimate of $2.5M. As of the current estimate, Metagenomi Inc’s year-ago sales were $11.16MFor the next quarter, 5 analysts are estimating revenue of $8.52M. There is a high estimate of $12.1M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 7 analysts have provided revenue estimates for MGX’s current fiscal year. The highest revenue estimate was $46.6M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $31.91M. In the same quarter a year ago, actual revenue was $52.3MBased on 6 analysts’ estimates, the company’s revenue will be $34.13M in the next fiscal year. The high estimate is $68M and the low estimate is $10M.
